The goal of these collaborative efforts is to identify and develop potential future therapeutic applications to heal chronic wounds by using stem cells harvested from menstrual blood. The partnership will enable Dr. Snyder to conduct research studies using Cryo-Cell's proprietary C'elle menstrual stem cell (MenSC) technology.
Chronic wounds, also called ulcers, are those which have a biological or physiological reason for not healing. There are various causes and many types of chronic wounds. Examples include a leg ulcer from a vein problem, a bed sore, or a foot wound caused by diabetes. "Millions of people worldwide may potentially benefit from future stem cell therapies to treat debilitating chronic wounds that can be life-impacting and devastating to patients and their families," said Mercedes A. Walton, Cryo-Cell's Chairman and CEO.
Approximately 5.7 million Americans currently suffer from chronic wounds at an estimated cost of $20 billion annually. This represents a significant burden to the U.S. health care system including patients, practitioners and insurance carriers. For example, the American Diabetes Association reports that more than 23 million Americans are diabetic. An estimated fifteen percent of these patients will develop an open sore, most commonly on the bottom of the foot, referred to as a diabetic foot ulcer. These wounds are particularly difficult to heal, impair the patient's quality of life and can lead to serious complications, such as amputations and higher mortality rates.
"Our ability to understand the science behind manipulating the chronic wound micro-environment, in combination with the healing activity of stem cells to discharge growth factors and encourage the formation of new blood vessels in the patient, may possibly lead to innovative breakthrough therapies," stated Dr. Snyder. "This research will determine if the C'elle stem cells found in menstrual blood may potentially mimic the wound healing process in therapeutic applications, along with the added benefit of being both non-invasive and cost-effective."
The C'elle service was introduced in November 2007 and enables women to collect and cryopreserve menstrual blood, which contains undifferentiated adult stem cells for future utilization by the donor or possibly first-degree relatives in a manner similar to umbilical cord blood stem cells.
Based on the continuing success of menstrual stem cells in the research setting, Cryo-Cell is actively expanding its portfolio of research collaborations with world renowned scientists committed to study this novel stem cell population for a the development of a broad range of regenerative and therapeutic uses.
About Robert J. Snyder, D.P.M., C.W.S.
In addition to treating patients in private practice, Dr. Snyder serves as medical director of the Wound Healing Center at University Hospital in Tamarac. Dr. Snyder is board certified in foot and ankle surgery by the American Board of Podiatric Surgery. He is a board certified wound specialist by the American Academy of Wound Management and is president elect of that organization. He is a fellow of the American College of Foot and Ankle Surgeons, the American Professional Wound Care Association and the College of Certified Wound Specialists. Dr. Snyder is also an executive board member of the Association for the Advancement of Wound Care. He was recently recognized in "Top 150 most influential podiatrists in the United States" by Podiatry Management Magazine. A frequent contributor to many medical journals, Dr. Snyder is currently consulting editor for Podiatry Management Magazine and a member of the editorial advisory boards of Ostomy Wound Management and Wounds. He is a Clinical Professor (Adjunct) at Temple University College of Podiatric Medicine and has authored over 100 papers for peer-reviewed and trade journals on topics relating to wound management and limb salvage. Dr. Snyder has done extensive research on many innovative wound care therapies. He is completing an MSc in Wound Healing and Tissue Science at the Wales College of Medicine, UK.
The C'elle(SM) service was introduced in November 2007 as the first and only service that empowers women to collect and cryopreserve menstrual flow containing undifferentiated adult stem cells for future utilization by the donor or possibly their first-degree relatives in a manner similar to umbilical cord blood stem cells. For more information, visit www.Celle.com.
About Cryo-Cell International, Inc. (OTCBB: CCEL.OB)
Based in Oldsmar, Florida, with nearly 185,000 clients worldwide, Cryo-Cell is one of the largest and most established family cord blood banks. ISO 9001:2000 certified and accredited by the AABB, Cryo-Cell operates in a state-of-the-art Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility. Cryo-Cell is a publicly traded company. OTC Bulletin Board Symbol: CCEL. For more information, please call 1-800-STOR-CELL (1-800-786-7235) or visit www.cryo-cell.com.